PARIS, Nov. 1, 2010 /PRNewswire-Asia/ --Sanofi-aventis (EURONEXT: SAN; NYSE: SNY) and BMP Sunstone Corporation (Nasdaq: BJGP) announced today that they have signed a definitive agreement under which Sanofi-aventis is to acquire all outstanding shares of BMP Sunstone for USD10 per share, for a total purchase price of USD520.6 million on a fully diluted basis. This price per share represents a 30% premium on BMP’s October 27, 2010 closing share price. E. J. McKay and Stephens Inc. acted as BMP Sunstone’s financial advisors, while Morgan Stanley represented Sanofi-aventis.
The acquisition of BMP Sunstone, which holds many leading Chinese pediatric and hygienic brands, will provide Sanofi-aventis with significant growth opportunities in the Chinese healthcare market, and specifically in its two largest categories: Vitamin & Minerals Supplements and Cough & Cold.
This transaction marks the largest Chinese pharmaceutical deal of the year, and is a prime example of the synergies and value that cross-border transactions can create. E. J. McKay CEO James Z. Li stated, “We are very pleased with the positive outcome. This acquisition will significantly boost Sanofi-aventis’ China presence, meanwhile creating significant value for BMP Sunstone’s shareholders. It is representative of the selectivity of our clients and the value and expertise E. J. McKay provides.”
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Reporting revenue of EUR29.3 billion in 2009, the company maintains over 100,000 employees in over 100 countries.
About BMP Sunstone
BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Through Sunstone, the Company manufactures leading pediatric and women's health products sold in pharmacies throughout the country. The Company also markets a portfolio of products under exclusive multi-year licenses into China, as well as provides pharmaceutical distribution.
About E. J. McKay
E. J. McKay is a Shanghai based investment banking group specialized in structuring complex cross-border mergers & acquisitions and merchant banking transactions. Through its offices and strategic partnerships, the firm is present in thirty major financial centers around the world. E. J. McKay has a dedicated focus on China, and advises transactions both inbound and outbound, representing clients both local and multinational.
Contact:
www.ejmckay.com, www.ejmckay.net
Natalie Hsiao
+86-21-5109-6266
natalie.hsiao@ejmckay.com
